Compare AbCellera Biologics Inc (ABCL) vs Cipher Mining Inc (CIFR) Price & Performance

ABCL's stock rose 7.07% to $10.00, buoyed by positive Phase 2 trial results for its menopause drug ABCL635, which demonstrated an 83% reduction in hot flashes (Business Wire, August 10, 2026). Despite negative profitability margins and cash burn, technical indicators show a bullish trend with strong moving average support. The company maintains a solid balance sheet with $625.61 million in cash and low debt, though revenue declined from $485 million in 2022 to $75 million in 2025.

The outlook hinges on clinical success and monetization of ABCL635, with a consensus price target of $15.50 implying 55% upside. Key risks include prolonged cash burn, drug development setbacks, and competitive pressures. Analyst sentiment is overwhelmingly bullish (91.67% buy ratings), but investors must weigh high valuation multiples against unproven commercial traction.

CIFR trades at $18.35, up 12.37% in the last 24 hours, but remains in a bearish technical trend. The company reported a Q2 2026 loss of $0.65 per share, missing estimates, with revenue declining and net losses widening. Despite negative profitability metrics, analyst consensus is unanimously bullish with a $31.78 price target, citing progress in its transition to AI data center operations and accelerated project deliveries.

The outlook hinges on successful execution of its AI infrastructure pivot, offering significant upside if targets are met, but high execution risks and persistent losses pose substantial threats to shareholder value. Investors face volatility amid the business model transition.